article Open AccessTop 1% cited
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2013 · Vol. 24(Suppl 4) · pp. vi24–vi32
Jonathan A. Ledermann✉(Cancer Institute (WIA))F. Raja(Cancer Institute (WIA))Christina Fotopoulou(Imperial College London)Antonio González-Martı́n(MD Anderson Cancer Center Madrid)Nicoletta Colombo(European Institute of Oncology)Cristiana Sessa(Ospedale San Giovanni Bellinzona)
Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer TreatmentsIntraperitoneal and Appendiceal MalignanciesMedicineOvarian carcinomaClinical PracticeOncologyCarcinomaEpithelial ovarian carcinomaInternal medicineOvarian cancerCancerFamily medicine
MeSH terms
Carcinoma, Ovarian EpithelialAge FactorsAgingAntineoplastic AgentsEuropeFemaleFollow-Up StudiesHumansNeoplasm Recurrence, LocalNeoplasm StagingNeoplasms, Glandular and EpithelialNeovascularization, PathologicOvarian NeoplasmsRisk FactorsTreatment Outcome
Funding
- Amgen
- GlaxoSmithKline
- Roche
- PharmaMar
Citations
1,110
FWCI
80.28
field-weighted impact
References
115
Percentile
100%
vs. same field & year
Citations per year
Cited by
Positron Emission Tomography (PET) in Oncology
Cancers · 2014 · 309 citations
Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells
Cell Death and Disease · 2019 · 424 citations
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
The Lancet Oncology · 2014 · 1,433 citations
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Frontiers in Oncology · 2017 · 280 citations
References
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
Cancer · 2009 · 1,581 citations
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study
Gynecologic Oncology · 1992 · 553 citations
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Gynecologic Oncology · 2006 · 307 citations
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
Journal of Clinical Oncology · 2002 · 2,313 citations
Cancer Statistics, 2009
CA A Cancer Journal for Clinicians · 2009 · 9,714 citations
Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
Gynecologic Oncology · 2008 · 369 citations
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Journal of Clinical Oncology · 2003 · 2,051 citations
Cancer incidence and mortality in Europe, 2004
Annals of Oncology · 2005 · 1,211 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.